|
|
|
Clinical Research Detail |
|
|
|
Title Of Study |
The study will assess canagliflozin in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events. Other objectives include evaluating the overall safety, tolerability, and effectiveness of canagliflozin.
|
|
|
Disease Condition |
Diabetes Mellitus, Type 2 Cardiovascular Diseases Risk Factors
|
|
|
Phase of Trial |
Phase-3
|
Discipline |
Diabetology
|
|
|
Start date of Trial |
12/9/2009
|
Closing Date of Trial |
12/9/2013
|
|
|
|